San Diego

Encore Capital Group Announces Final Results of Tender Offer

Retrieved on: 
Thursday, December 9, 2021
Transfer, Bangladesh Securities and Exchange Commission, Forward-looking statement, NASDAQ, GLOBE, SAN, ECPG, Encore Capital Group, USA, LLC, Credit Suisse, U.S. Securities and Exchange Commission, Security (finance)

SAN DIEGO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Encore Capital Group, Inc. (NASDAQ: ECPG) (Encore) announced today the final results of its modified Dutch auction tender offer to purchase with cash up to $300 million of shares (the shares) of its common stock (the common stock) which expired one minute after 11:59 P.M. (New York City time) on December 2, 2021.

Key Points: 
  • SAN DIEGO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Encore Capital Group, Inc. (NASDAQ: ECPG) (Encore) announced today the final results of its modified Dutch auction tender offer to purchase with cash up to $300 million of shares (the shares) of its common stock (the common stock) which expired one minute after 11:59 P.M. (New York City time) on December 2, 2021.
  • The depositary will promptly pay for the shares of common stock accepted for purchase pursuant to the tender offer.
  • Since the beginning of 2021, through a combination of the tender offer and share repurchases made by Encore prior to the tender, Encore has purchased approximately 22% of its total shares of common stock outstanding as of December 31, 2020.
  • Georgeson LLC is serving as information agent for the tender offer and American Stock Transfer & Trust Company, LLC is serving as the depositary for the tender offer.

Maravai LifeSciences Announces Establishment of New Charitable Foundation

Retrieved on: 
Thursday, December 9, 2021
U.S. Securities and Exchange Commission, Research, GLOBE, Technology, Safety, Private Securities Litigation Reform Act, Vaccine, Melamaravakkadu, Foundation, Internal Revenue Code, Time, Public health, Revenue stream, Internal Revenue Service, NASDAQ, SAN, Annual report, Pharmaceutical industry

SAN DIEGO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced it is establishing a new charitable foundation to promote causes tied to Maravais mission.

Key Points: 
  • SAN DIEGO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced it is establishing a new charitable foundation to promote causes tied to Maravais mission.
  • The Maravai LifeSciences Foundation anticipates focusing on charitable, scientific, and educational endeavors, with particular emphasis on advancing scientific education and innovation, supporting local communities in which we operate, promoting public health and access to healthcare, and advocating for inclusion and diversity.
  • In addition, the Foundation intends to establish a match for Maravai employee giving to help strengthen a broad range of nonprofit programs in communities where Maravai has a presence.
  • Maravai is committed to being a strong corporate citizen, and the new Maravai Foundation will allow us to make an even bigger impact in our communities, said Carl Hull, Maravais Chief Executive Officer.

Endera Announces New All-Electric Powertrain

Engineering, Research, University, GLOBE, Technology, Longevity, EV, Safety, DC, Efficiency, Industry, Maintenance, Ownership, Adoption, Tesla, Solution, Hospital, SAN, Taxicab, Renewable energy

SAN DIEGO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Endera, a technology company specializing in all-electric commercial vehicles, charging infrastructure, and software solutions, announced the launch of its all-electric powertrain for Class 3 and 4 zero-emission commercial vehicles.

Key Points: 
  • The companys proprietary powertrain enables end-to-end control of the production process while employing a vertical integration strategy that continues to drive down the price of electric vehicles.
  • Enderas research and development team applied lessons learned from their years of collective experience in electric vehicles towards the development of its proprietary powertrain.
  • Working with top quality components, industry-leading suppliers, and using cutting-edge technology, the electric powertrain will be produced in Enderas Ottawa Ohio Manufacturing facility .
  • Endera is a technology company, specializing in smart electric commercial vehicles, charging stations, and software solutions.

Guardion Health Sciences Appoints Experienced Healthcare Executive Michaela Griggs to its Board of Directors

Retrieved on: 
Thursday, December 9, 2021
U.S. Securities and Exchange Commission, Physician, Company, GLOBE, SEC, Securities Act of 1933, Knowledge, Business, Growth, Intention, Board of directors, British and Irish Orthoptic Society, Allergan, Patient, News, Director, Nature, Business administration, Securities Exchange Act of 1934, Biophysical environment, Board, Social, Bayer, COVID-19, Marketing, Social Security Government Pension Offset, DBO, Risk, Acquisition, Compliance, London School of Business and Finance, Management, Pharmaceutical industry

HOUSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (Guardion or the Company), a clinical nutrition and diagnostics company that develops clinically supported nutrition, medical foods, supplements, and medical devices, announced today that Michaela Griggs, a seasoned healthcare executive, has been appointed to its Board of Directors.

Key Points: 
  • HOUSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (Guardion or the Company), a clinical nutrition and diagnostics company that develops clinically supported nutrition, medical foods, supplements, and medical devices, announced today that Michaela Griggs, a seasoned healthcare executive, has been appointed to its Board of Directors.
  • We are very excited to welcome Michaela to our Board of Directors.
  • Her marketing acumen and deep experience in both the consumer-driven and healthcare professional-driven markets make her an excellent addition to our already strong Board of Directors, commented Robert N. Weingarten, Guardions Chairman of the Board of Directors.
  • From 2017 through 2020, Ms. Griggs served as Executive Vice President at Barco Uniforms Health Care & Identity Divisions.

Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management Supporting th

Retrieved on: 
Thursday, December 9, 2021
Fast Track, FDA, Pivotal trial, Leg, Pharmaceutical industry

PALO ALTO, Calif., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento), today announced highly significant positive top-line results from its SP-102 (SEMDEXA) Phase 3 Pivotal Trial C.L.E.A.R.

Key Points: 
  • PALO ALTO, Calif., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento), today announced highly significant positive top-line results from its SP-102 (SEMDEXA) Phase 3 Pivotal Trial C.L.E.A.R.
  • Program, a corticosteroid injectable dexamethasone sodium phosphate viscous gel for the treatment of lumbosacral radicular pain, or sciatica.
  • The trial enrolled 401 low back pain subjects with unilateral intervertebral disc herniation in lumbosacral spine resulting in radicular pain symptoms of moderate to severe leg pain.
  • The two key secondary endpoints assessing Oswestry Disability Index (ODI) and Time to open-label repeat injection had also demonstrated highly statistically significant results.

Bionano Genomics Announces 2022 Symposium Featuring Four Consecutive Days of OGM Presentations and Live Panel Discussions Delivered by 25 Different Customers Across a Wide Range of Genetic Disease and Cancer Applications

Retrieved on: 
Thursday, December 9, 2021
U.S. Securities and Exchange Commission, Lists of diseases, Medicine, Company, FACMG, Forward-looking statement, Research, GLOBE, NGS, Security (finance), Private Securities Litigation Reform Act, Infertility, Patient, CEO, Software, Autism, Hospital Insurance and Diagnostic Services Act, Cancer, OGM, Lineagen, Education, B-ALL, CLL, Standard of care, Cytogenetics, COVID-19, Adult, Adoption, Doctor of Philosophy, Acute myeloid leukemia, PST, Solution, Genomics, Hospital, Biology, Genome, Annual report, SAN, Q&A, Lymphatic system, Medical imaging, Pharmaceutical industry, Agriculture

Each day will feature oral customer presentations, a live panel with Q&A and a scientific poster exhibit within the virtual exhibition hall.

Key Points: 
  • Each day will feature oral customer presentations, a live panel with Q&A and a scientific poster exhibit within the virtual exhibition hall.
  • Last years Symposium was a landmark event for Bionano, which highlighted the utility of OGM for constitutional and cancer cytogenomics applications with over 4,500 registered attendees.
  • At Bionano, we are working to transform the way the world sees the genome, said Erik Holmlin, PhD, President and CEO of Bionano Genomics.
  • After the scientific presentations, the speakers will join for a live panel discussion and Q&A moderated by Dr. Chaubey.

GA-ASI Announces New Mojave UAS

Retrieved on: 
Thursday, December 9, 2021
Aircraft, Lynx, ISR, Twitter, GLOBE, General Atomics, Technology, Aperture synthesis, General Atomics MQ-9 Reaper, RPA, General Atomics Aeronautical Systems, Electro, Weapon, Predation, Nature, SIGINT, Avenger, Intelligence cycle, Employment, Radar, STOL, LinkedIn, SAN, UAS, Instrumentation

Mojave provides options for forward-basing operations without the need for typical airport runways or infrastructure.

Key Points: 
  • Mojave provides options for forward-basing operations without the need for typical airport runways or infrastructure.
  • These innovations make Mojave the perfect UAS to perform armed overwatch, attack and armed reconnaissance missions.
  • "We're proud to bring these extraordinary capabilities to our Predator line of UAS," said GA-ASI CEO Linden Blue.
  • This revolutionary design, based on seven million flight hours of UAS experience, increases expeditionary employment options making Mojave a real game-changer."

Fate Therapeutics to Host Virtual Event at the 2021 ASH Annual Meeting

Retrieved on: 
Wednesday, December 8, 2021
FC, Canadian Aviation Regulations, Trastuzumab, Investor, Company, CA, GLOBE, B-cell lymphoma, Immunotherapy, CAR, Lymphoma, NK, Therapy, ADCC, Patient, Downregulation and upregulation, Acute myeloid leukemia, Cancer, Rituximab, Exposition, Antibody, CD16, IPSC, CLL, Maintenance, Chronic lymphocytic leukemia, CD19, Patent, Immunoglobulin G, FDA, NASDAQ, SAN, Society, Cetuximab, Destiny, ASH, Vaccine

The archived webcast will be available on the Company's website beginning approximately two hours after the event.

Key Points: 
  • The archived webcast will be available on the Company's website beginning approximately two hours after the event.
  • The event is not an official program of the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.
  • Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications.
  • Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer.

MegaFans Finds Traction, Milestone, Distributing NFTs and Cryptos for eSports

Retrieved on: 
Wednesday, December 8, 2021
Advertising, Esports, GLOBE, IAPS, Megafan, Community Participation, Mobile, CEO, USD, Non-fungible token, Blockchain, Solution, SAN, Traction, Social media, Video game, Cryptocurrency

"This is a huge milestone for MegaFans," says CEO, Jeff Donnelley.

Key Points: 
  • "This is a huge milestone for MegaFans," says CEO, Jeff Donnelley.
  • "We achieved our goal to surpass break-even economics against ROAS, which makes this a sustainable business model, and we found traction using blockchain solutions and crypto products for our global audience.
  • We couldn't be happier with the results."
  • Launchpool Labs incubator is a 90-day intensive development program focused on building communities and value around startups in the blockchain sector.

Cloudbeds Horizon launches to empower hospitality schools to upskill students in cloud technology

Retrieved on: 
Wednesday, December 8, 2021
University, GLOBE, Technology, Bumrungrad International Hospital, Automation, Learning, Curriculum, EHL, Discovery, CEO, Industry, Â, Partnership, VP, SAN, School, Student, Medicine

Cloudbeds Horizon launches following a successful pilot program with EHL , the worlds most prestigious hospitality management school.

Key Points: 
  • Cloudbeds Horizon launches following a successful pilot program with EHL , the worlds most prestigious hospitality management school.
  • Cloudbeds Horizon partners with hospitality schools and universities worldwide to provide access to its innovative cloud software, knowledge base, and on-demand educational materials to help upskill students in modern cloud software and technology.
  • For the EHL pilot, Cloudbeds partnered with the universitys hospitality technology class to develop a weeklong curriculum for students to gain experience managing test properties through the Cloudbeds Hospitality Platform.
  • Cloudbeds Horizon is now available to any hospitality education program worldwide, with universities receiving special educational licenses for students to learn directly on the Cloudbeds Hospitality Platform .